Dear all, I think I am now moving to Bluesky. It may deteriorate as did Twitter sooner or later but for the moment it seems OK :) See you there, if you agree. Toshi
@Toshi_FRKW
- 10 Followers
- 8 Following
- 16 Posts
Psychiatrist, turned cognitive-behavior therapist, turned clinical epidemiologist, turned smartphone app developer
Joar Øveraas HalvorsenThe Psychotherapy in MDMA-Assisted Psychotherapy. https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2824481 In this viewpoint, lead by the marvellous
@IoanaA_Cristea, we argue that the psychotherapy component plays a critical role in assessing the validity of the trials of MDMA-assisted psychotherapy for PTSD.
@IoanaA_Cristea, we argue that the psychotherapy component plays a critical role in assessing the validity of the trials of MDMA-assisted psychotherapy for PTSD.
The SWD should inform the calculation of the sample size for the next trial. But it is not exactly the d for the sample size calculation. Please see: https://www.youtube.com/watch?v=1VgNnGWqhcI
Is the effect of antidepressants worth the side-effects? Only those who need them can tell!
What should we use when interpreting the results of a clinical trial -- are the differences between the drug and the placebo big, small or negligible? Is it meaningful for the patients? People have been using the MCID (minimal clinical importance difference) for this purpose for years but this practice is logically wrong. We advocate the use of the SWD (smallest worthwhile difference). Here is a video explaining this difference by Prof Salanti of the University of Bern. https://www.youtube.com/watch?v=1VgNnGWqhcI